Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.

[1]  J. Grandis,et al.  Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer , 2007, Clinical Cancer Research.

[2]  N. Spector,et al.  HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors , 2007, Breast Cancer Research.

[3]  M. Bower,et al.  Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[4]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[5]  C. Jackisch.  HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. , 2006, The oncologist.

[6]  J. Buolamwini,et al.  Targeting EGFR and HER‐2 receptor tyrosine kinases for cancer drug discovery and development , 2006, Medicinal research reviews.

[7]  Lisa Jarvis,et al.  BATTLING BREAST CANCER , 2006 .

[8]  J. Levin,et al.  Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[9]  P. Scherle,et al.  Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.

[10]  J. Minna,et al.  Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. , 2006, Cancer cell.

[11]  J. Fridman,et al.  Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Wynn,et al.  Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells , 2006, Cancer biology & therapy.

[13]  S. Mobashery,et al.  Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.

[14]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[15]  J. Baselga,et al.  Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Nerlich,et al.  Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach , 2005, Expert review of anticancer therapy.

[17]  A. Jeng,et al.  The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.

[18]  Geoffrey S Ginsburg,et al.  Targeted therapies for cancer 2004. , 2004, American journal of clinical pathology.

[19]  J. Levin.  The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. , 2004, Current topics in medicinal chemistry.

[20]  S. Meroueh,et al.  Quest for selectivity in inhibition of matrix metalloproteinases. , 2004, Current topics in medicinal chemistry.

[21]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[22]  F. C. Nelson,et al.  The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. , 2001, Bioorganic & medicinal chemistry letters.

[23]  J. Crespo,et al.  Asymmetric hydrolysis of a meso-diester using pig liver esterase immobilised in hollow fibre ultrafiltration membrane , 2000 .

[24]  S. Hanessian,et al.  Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[25]  S. Davidsen,et al.  Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. , 1998, Bioorganic & medicinal chemistry letters.

[26]  M. T. Brewer,et al.  Identification and Characterization of a Pro-tumor Necrosis Factor-α-processing Enzyme from the ADAM Family of Zinc Metalloproteases* , 1997, The Journal of Biological Chemistry.

[27]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[28]  W. Hagmann,et al.  Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides , 1996 .

[29]  S. Chandler,et al.  Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.

[30]  L. Liotta,et al.  Cloning and characterization of human tumor cell interstitial collagenase. , 1990, Cancer research.

[31]  Y. Otani,et al.  The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. , 1988, The Journal of biological chemistry.

[32]  J. Fridman,et al.  Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis. , 2008, Bioorganic & medicinal chemistry letters.

[33]  Diane Joseph-McCarthy,et al.  Identification of potent and selective TACE inhibitors via the S1 pocket. , 2007, Bioorganic & medicinal chemistry letters.

[34]  S. Keam,et al.  Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. , 2006, Drugs.